BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1289 related articles for article (PubMed ID: 20813259)

  • 1. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.
    Chao MP; Alizadeh AA; Tang C; Myklebust JH; Varghese B; Gill S; Jan M; Cha AC; Chan CK; Tan BT; Park CY; Zhao F; Kohrt HE; Malumbres R; Briones J; Gascoyne RD; Lossos IS; Levy R; Weissman IL; Majeti R
    Cell; 2010 Sep; 142(5):699-713. PubMed ID: 20813259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD47/SIRPα blocking enhances CD19/CD3-bispecific T cell engager antibody-mediated lysis of B cell malignancies.
    Xu L; Wang S; Li J; Li B
    Biochem Biophys Res Commun; 2019 Feb; 509(3):739-745. PubMed ID: 30611570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
    Liu J; Wang L; Zhao F; Tseng S; Narayanan C; Shura L; Willingham S; Howard M; Prohaska S; Volkmer J; Chao M; Weissman IL; Majeti R
    PLoS One; 2015; 10(9):e0137345. PubMed ID: 26390038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy.
    Chao MP; Tang C; Pachynski RK; Chin R; Majeti R; Weissman IL
    Blood; 2011 Nov; 118(18):4890-901. PubMed ID: 21828138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells.
    Piccione EC; Juarez S; Liu J; Tseng S; Ryan CE; Narayanan C; Wang L; Weiskopf K; Majeti R
    MAbs; 2015; 7(5):946-56. PubMed ID: 26083076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice.
    Smith MR; Joshi I; Jin F; Obasaju C
    BMC Cancer; 2005 Aug; 5():103. PubMed ID: 16109167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20.
    Weiskopf K; Anderson KL; Ito D; Schnorr PJ; Tomiyasu H; Ring AM; Bloink K; Efe J; Rue S; Lowery D; Barkal A; Prohaska S; McKenna KM; Cornax I; O'Brien TD; O'Sullivan MG; Weissman IL; Modiano JF
    Cancer Immunol Res; 2016 Dec; 4(12):1072-1087. PubMed ID: 27856424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody.
    Ni H; Cao L; Wu Z; Wang L; Zhou S; Guo X; Gao Y; Jing H; Wu M; Liu Y; Ding J; Zhang P; Zhou Y; Chen B; Xiong Y; Sun J; Prinz B; Baruah H; Geoghegan J; Yu M; Wu W; Liu J
    Cancer Immunol Immunother; 2022 Feb; 71(2):353-363. PubMed ID: 34165607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
    Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
    Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted inhibition of CD47-SIRPα requires Fc-FcγR interactions to maximize activity in T-cell lymphomas.
    Jain S; Van Scoyk A; Morgan EA; Matthews A; Stevenson K; Newton G; Powers F; Autio A; Louissaint A; Pontini G; Aster JC; Luscinskas FW; Weinstock DM
    Blood; 2019 Oct; 134(17):1430-1440. PubMed ID: 31383641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD47 Agent Boosts Macrophage Activity in NHL.
    Cancer Discov; 2019 Jan; 9(1):7-8. PubMed ID: 30464001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy.
    Ribeiro ML; Profitós-Pelejà N; Santos JC; Blecua P; Reyes-Garau D; Armengol M; Fernández-Serrano M; Miskin HP; Bosch F; Esteller M; Normant E; Roué G
    Front Immunol; 2023; 14():1130052. PubMed ID: 37153563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.
    Majeti R; Chao MP; Alizadeh AA; Pang WW; Jaiswal S; Gibbs KD; van Rooijen N; Weissman IL
    Cell; 2009 Jul; 138(2):286-99. PubMed ID: 19632179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages.
    Zeller T; Lutz S; Münnich IA; Windisch R; Hilger P; Herold T; Tahiri N; Banck JC; Weigert O; Moosmann A; von Bergwelt-Baildon M; Flamann C; Bruns H; Wichmann C; Baumann N; Valerius T; Schewe DM; Peipp M; Rösner T; Humpe A; Kellner C
    Front Immunol; 2022; 13():929339. PubMed ID: 36389667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD47 limits antibody dependent phagocytosis against non-malignant B cells.
    Gallagher S; Turman S; Lekstrom K; Wilson S; Herbst R; Wang Y
    Mol Immunol; 2017 May; 85():57-65. PubMed ID: 28208074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphocyte subsets and viral load in patients with HIV-associated non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibody and chemotherapy.
    De Paoli P; Vaccher E; Tedeschi R; Caffau C; Zanussi S; Bortolin MT; Crepaldi C; Spina M; Tirelli U
    Cancer Immunol Immunother; 2001 May; 50(3):157-62. PubMed ID: 11419183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
    Advani R; Flinn I; Popplewell L; Forero A; Bartlett NL; Ghosh N; Kline J; Roschewski M; LaCasce A; Collins GP; Tran T; Lynn J; Chen JY; Volkmer JP; Agoram B; Huang J; Majeti R; Weissman IL; Takimoto CH; Chao MP; Smith SM
    N Engl J Med; 2018 Nov; 379(18):1711-1721. PubMed ID: 30380386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
    Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
    Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.